Oskar Hansson

List of Publications by Year in Descending Order

484 papers	**26,071** citations	**85** h-index	**144** g-index
564 ext. papers	**34,124** ext. citations	**7.2** avg, IF	**7.3** L-index

#	Paper	IF	Citations
484	Central nervous system monoaminergic activity in hip osteoarthritis patients with disabling pain: associations with pain severity and central sensitization.. *Pain Reports*, **2022**, 7, e988	3.5	1
483	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. *JAMA Neurology*, **2022**,	17.2	9
482	*Neurology*, **2022**,	6.5	3
481	Cellular localization of p-tau217 in brain and its association with p-tau217 plasma levels.. *Acta Neuropathologica Communications*, **2022**, 10, 3	7.3	4
480	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings.. *Alzheimer's and Dementia*, **2022**,	1.2	2
479	Components of gait in people with and without mild cognitive impairment.. *Gait and Posture*, **2022**, 93, 83-89	2.6	
478	The accuracy and robustness of plasma biomarker models for amyloid PET positivity.. *Alzheimer's Research and Therapy*, **2022**, 14, 26	9	4
477	The Neuroinflammatory Acute Phase Response in Parkinsonian-Related Disorders.. *Movement Disorders*, **2022**,	7	1
476	Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.. *journal of prevention of Alzheimer's disease, The*, **2022**, 9, 197-210	3.8	7
475	Subtypes of Alzheimer's disease: questions, controversy, and meaning.. *Trends in Neurosciences*, **2022**,	13.3	3
474	Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients.. *Alzheimer's Research and Therapy*, **2022**, 14, 46	9	1
473	Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217.. *Alzheimer's Research and Therapy*, **2022**, 14, 67	9	0
472	Tau PET Imaging in Neurodegenerative Disorders. *Journal of Nuclear Medicine*, **2022**, 63, 20S-26S	8.9	2
471	Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.. *JAMA Neurology*, **2021**,	17.2	10
470	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. *Alzheimer's and Dementia*, **2021**, 17,	1.2	3
469	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives.. *Australian and New Zealand Journal of Psychiatry*, **2021**, 48674211058684	2.6	1
468	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. *Lancet Neurology, The*, **2021**,	24.1	40

467	Insights on Genetic and Environmental Factors in Parkinson's Disease from a Regional Swedish Case-Control Cohort. *Journal of Parkinson's Disease*, **2021**,	5.3	1
466	Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. *Alzheimer's and Dementia*, **2021**,	1.2	12
465	The global Alzheimer's Association round robin study on plasma amyloid β methods. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2021**, 13, e12242	5.2	2
464	Cerebrospinal Fluid Biomarker Levels as Markers for Nursing Home Placement and Survival Time in Alzheimer's Disease. *Current Alzheimer Research*, **2021**, 18, 573-584	3	2
463	Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer's disease. *Scientific Reports*, **2021**, 11, 19853	4.9	0
462	Association of Enlarged Perivascular Spaces and Measures of Small Vessel and Alzheimer Disease. *Neurology*, **2021**, 96, e193-e202	6.5	8
461	2020 update on the clinical validity of cerebrospinal fluid amyloid, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2121-2139	8.8	18
460	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β and tau. *Alzheimer's and Dementia*, **2021**, 17, 1575-1582	1.2	12
459	Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment. *Alzheimer's Research and Therapy*, **2021**, 13, 68	9	35
458	The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2140-2156	8.8	31
457	Early stages of tau pathology and its associations with functional connectivity, atrophy and memory. *Brain*, **2021**, 144, 2771-2783	11.2	10
456	Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2086-2096	8.8	4
455	The strategic biomarker roadmap for the validation of Alzheimer's diagnostic biomarkers: methodological update. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2070-2085	8.8	10
454	Four distinct trajectories of tau deposition identified in Alzheimer's disease. *Nature Medicine*, **2021**, 27, 871-881	50.5	81
453	A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [F]flutemetamol amyloid PET images. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2183-2199	8.8	3
452	Heterogeneous distribution of tau pathology in the behavioural variant of Alzheimer's disease. *Journal of Neurology, Neurosurgery and Psychiatry*, **2021**,	5.5	8
451	Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments-EQ-5D data from the Swedish BioFINDER study. *Alzheimer's and Dementia*, **2021**, 17, 1832-1842	1.2	0
450	Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer's disease. *Alzheimer's and Dementia*, **2021**,	1.2	7

449	A multicenter comparison of [F]flortaucipir, [F]RO948, and [F]MK6240 tau PET tracers to detect a common target ROI for differential diagnosis. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2295-2305	8.8	11
448	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. *Nature Medicine*, **2021**, 27, 1034-1042	50.5	56
447	Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. *EMBO Molecular Medicine*, **2021**, 13, e14022	12	22
446	Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. *Brain*, **2021**, 144, 2826-2836	11.2	12
445	The BIN1 rs744373 Alzheimer's disease risk SNP is associated with faster Aβ-associated tau accumulation and cognitive decline. *Alzheimer's and Dementia*, **2021**,	1.2	4
444	Biomarkers for neurodegenerative diseases. *Nature Medicine*, **2021**, 27, 954-963	50.5	69
443	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau. *Alzheimer's and Dementia*, **2021**,	1.2	12
442	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. *Nature Communications*, **2021**, 12, 3555	17.4	23
441	A multicentre validation study of the diagnostic value of plasma neurofilament light. *Nature Communications*, **2021**, 12, 3400	17.4	51
440	Structural and functional neuroimaging changes associated with cognitive impairment and dementia in Parkinson's disease. *Psychiatry Research - Neuroimaging*, **2021**, 312, 111273	2.9	2
439	Tau PET correlates with different Alzheimer's disease-related features compared to CSF and plasma p-tau biomarkers. *EMBO Molecular Medicine*, **2021**, 13, e14398	12	8
438	The Effects of Tau, Amyloid, and White Matter Lesions on Mobility, Dual Tasking, and Balance in Older People. *Journals of Gerontology - Series A Biological Sciences and Medical Sciences*, **2021**, 76, 683-691	6.4	2
437	Acute phase markers in CSF reveal inflammatory changes in Alzheimer's disease that intersect with pathology, APOE ε4, sex and age. *Progress in Neurobiology*, **2021**, 198, 101904	10.9	8
436	Association Between Apolipoprotein E ε2 vs ε4, Age, and β-Amyloid in Adults Without Cognitive Impairment. *JAMA Neurology*, **2021**, 78, 229-235	17.2	10
435	Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. *Nature Aging*, **2021**, 1, 114-123		34
434	Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2021**, 8, 259-265	5.3	9
433	Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease. *Movement Disorders*, **2021**, 36, 767-771	7	8
432	Untangling the association of amyloid-β and tau with synaptic and axonal loss in Alzheimer's disease. *Brain*, **2021**, 144, 310-324	11.2	34

431	Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. *JAMA Neurology*, **2021**, 78, 149-156	17.2	62
430	The impact of demographic, clinical, genetic, and imaging variables on tau PET status. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2245-2258	8.8	8
429	SCRT1 is a novel beta cell transcription factor with insulin regulatory properties. *Molecular and Cellular Endocrinology*, **2021**, 521, 111107	4.4	2
428	Reporting frequency of radiology findings increases after introducing visual rating scales in the primary care diagnostic work up of subjective and mild cognitive impairment. *European Radiology*, **2021**, 31, 666-673	8	3
427	Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. *Current Opinion in Neurology*, **2021**, 34, 266-274	7.1	14
426	Mild behavioral impairment and its relation to tau pathology in preclinical Alzheimer's disease. *Translational Psychiatry*, **2021**, 11, 76	8.6	32
425	Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. *Scientific Reports*, **2021**, 11, 1965	4.9	9
424	Biomarker testing in MCI patients-deciding who to test. *Alzheimer's Research and Therapy*, **2021**, 13, 14	9	0
423	Neuroligin-1 in brain and CSF of neurodegenerative disorders: investigation for synaptic biomarkers. *Acta Neuropathologica Communications*, **2021**, 9, 19	7.3	8
422	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. *Alzheimer's Research and Therapy*, **2021**, 13, 38	9	4
421	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2110-2120	8.8	9
420	Clinical validity of increased cortical uptake of [F]flortaucipir on PET as a biomarker for Alzheimer's disease in the context of a structured 5-phase biomarker development framework. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2097-2109	8.8	14
419	Time between milestone events in the Alzheimer's disease amyloid cascade. *NeuroImage*, **2021**, 227, 117676	7.9	5
418	Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease. *Brain*, **2021**,	11.2	31
417	Inter-modality assessment of medial temporal lobe atrophy in a non-demented population: application of a visual rating scale template across radiologists with varying clinical experience. *European Radiology*, **2021**, 1	8	
416	Tau-related grey matter network breakdown across the Alzheimer's disease continuum. *Alzheimer's Research and Therapy*, **2021**, 13, 138	9	4
415	Management of Alzheimer's disease takes a leap forward. *Lancet Neurology, The*, **2021**, 20, 586-587	24.1	1
414	Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. *JAMA Neurology*, **2021**, 78, 961-971	17.2	29

413	Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays. *Neurology*, **2021**, 97, e1681-e1694	6.5	10
412	Head-to-Head Comparison of 8 Plasma Amyloid-β42/40 Assays in Alzheimer Disease. *JAMA Neurology*, **2021**, 78, 1375-1382	17.2	29
411	Tau pathology mediates age effects on medial temporal lobe structure. *Neurobiology of Aging*, **2021**, 109, 135-144	5.6	1
410	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. *Lancet Neurology, The*, **2021**, 20, 739-752	24.1	43
409	Comparing ATN-T designation by tau PET visual reads, tau PET quantification, and CSF PTau181 across three cohorts. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2259-2271	8.8	4
408	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. *Alzheimer's and Dementia*, **2021**, 17, 1145-1156	1.2	48
407	Sex differences in off-target binding using tau positron emission tomography. *NeuroImage: Clinical*, **2021**, 31, 102708	5.3	5
406	The protective gene dose effect of the APOE ε2 allele on gray matter volume in cognitively unimpaired individuals. *Alzheimer's and Dementia*, **2021**,	1.2	4
405	Association of CSF Aβ38 Levels With Risk of Alzheimer Disease-Related Decline.. *Neurology*, **2021**,	6.5	2
404	Validation of Plasma Amyloid-β42/40 for Detecting Alzheimer Disease Amyloid Plaques.. *Neurology*, **2021**,	6.5	7
403	Blood-based biomarkers for Alzheimer's disease. *EMBO Molecular Medicine*, **2021**, e14408	12	7
402	Sex differences in blood-based biomarkers in individuals with autosomal dominant Alzheimer's disease.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e055011	1.2	
401	Modeling patient-specific tau spreading patterns in Alzheimer's disease: Towards precision medicine. *Alzheimer's and Dementia*, **2020**, 16, e040587	1.2	1
400	The accumulation rate of tau aggregates is higher in females and younger individuals. *Alzheimer's and Dementia*, **2020**, 16, e043876	1.2	1
399	Improved performance of Elecsys CSF Abeta measurement achieved using the simple, unified routine-use protocol for CSF collection. *Alzheimer's and Dementia*, **2020**, 16, e047394	1.2	
398	Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies. *Nature Communications*, **2020**, 11, 6252	17.4	15
397	High circulating levels of midregional proenkephalin A predict vascular dementia: a population-based prospective study. *Scientific Reports*, **2020**, 10, 8027	4.9	3
396	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE ε4 carriers. *Scientific Reports*, **2020**, 10, 8233	4.9	4

395	Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders. *JAMA Neurology*, **2020**, 77, 955-965	17.2	71
394	The implications of different approaches to define AT(N) in Alzheimer disease. *Neurology*, **2020**, 94, e2233-e2244	8.5	14
393	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease. *Nature Communications*, **2020**, 11, 2612	17.4	118
392	Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. *Journal of Alzheimer's Disease*, **2020**, 76, 27-31	4.3	5
391	Medial temporal atrophy in preclinical dementia: Visual and automated assessment during six year follow-up. *NeuroImage: Clinical*, **2020**, 27, 102310	5.3	5
390	Longitudinal degeneration of the basal forebrain predicts subsequent dementia in Parkinson's disease. *Neurobiology of Disease*, **2020**, 139, 104831	7.5	18
389	The age-related effect on cognitive performance in cognitively healthy elderly is mainly caused by underlying AD pathology or cerebrovascular lesions: implications for cutoffs regarding cognitive impairment. *Alzheimer's Research and Therapy*, **2020**, 12, 30	9	6
388	Medial temporal lobe connectivity and its associations with cognition in early Alzheimer's disease. *Brain*, **2020**, 143, 1233-1248	11.2	59
387	Towards unconstrained compartment modeling in white matter using diffusion-relaxation MRI with tensor-valued diffusion encoding. *Magnetic Resonance in Medicine*, **2020**, 84, 1605-1623	4.4	33
386	Assessment of Demographic, Genetic, and Imaging Variables Associated With Brain Resilience and Cognitive Resilience to Pathological Tau in Patients With Alzheimer Disease. *JAMA Neurology*, **2020**, 77, 632-642	17.2	36
385	Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. *Nature Medicine*, **2020**, 26, 379-386	50.5	292
384	Quantification of total apolipoprotein E and its isoforms in cerebrospinal fluid from patients with neurodegenerative diseases. *Alzheimer's Research and Therapy*, **2020**, 12, 19	9	11
383	[18F]Flortaucipir distinguishes Alzheimer's disease from progressive supranuclear palsy pathology in a mixed-pathology case. *Acta Neuropathologica*, **2020**, 139, 411-413	14.3	1
382	Beta-blocker therapy and risk of vascular dementia: A population-based prospective study. *Vascular Pharmacology*, **2020**, 125-126, 106649	5.9	4
381	Functional brain architecture is associated with the rate of tau accumulation in Alzheimer's disease. *Nature Communications*, **2020**, 11, 347	17.4	81
380	Alcohol Consumption and Risk of Parkinson's Disease: Data From a Large Prospective European Cohort. *Movement Disorders*, **2020**, 35, 1258-1263	7	8
379	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease. *Nature Communications*, **2020**, 11, 1683	17.4	133
378	Relationship between cortical iron and tau aggregation in Alzheimer's disease. *Brain*, **2020**, 143, 1341-1349	11.2	42

377 Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. *Science Advances*, **2020**, 6, eaaz2387 — 14.3 — 88

376 Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. *Neurology*, **2020**, 95, e3026-e3035 — 6.5 — 13

375 Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia. *Nature Communications*, **2020**, 11, 619 — 17.4 — 37

374 The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. *Brain*, **2020**, 143, 3805-3815 — 11.2 — 18

373 Cerebrospinal fluid neurogranin in an inducible mouse model of neurodegeneration: A translatable marker of synaptic degeneration. *Neurobiology of Disease*, **2020**, 134, 104645 — 7.5 — 12

372 Distinct tau PET patterns in atrophy-defined subtypes of Alzheimer's disease. *Alzheimer's and Dementia*, **2020**, 16, 335-344 — 1.2 — 31

371 Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia. *Annals of Neurology*, **2020**, 87, 52-62 — 9.4 — 29

370 Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer's disease. *BMC Neurology*, **2020**, 20, 10 — 3.1 — 22

369 Cerebrospinal fluid tau fragment correlates with tau PET: a candidate biomarker for tangle pathology. *Brain*, **2020**, 143, 650-660 — 11.2 — 33

368 Cerebrospinal fluid levels of neurogranin in Parkinsonian disorders. *Movement Disorders*, **2020**, 35, 513-518 — 7 — 11

367 Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. *Brain*, **2020**, 143, 3234-3241 — 12.4 — 63

366 Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies. *Nature Structural and Molecular Biology*, **2020**, 27, 1125-1133 — 17.6 — 35

365 Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. *Lancet Neurology, The*, **2020**, 19, 951-962 — 24.1 — 95

364 Derivation and utility of an Aβ PET pathology accumulation index to estimate Aβ load. *Neurology*, **2020**, 95, e2834-e2844 — 6.5 — 3

363 Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer's dementia. *Alzheimer's Research and Therapy*, **2020**, 12, 158 — 9 — 3

362 Patient-centered connectivity-based prediction of tau pathology spread in Alzheimer's disease. *Science Advances*, **2020**, 6, — 14.3 — 26

361 LifeTime and improving European healthcare through cell-based interceptive medicine. *Nature*, **2020**, 587, 377-386 — 50.4 — 56

360 Allele drop-out and the stochastic threshold **2020**, 89-110

341	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. *Lancet Neurology, The*, **2019**, 18, 1034-1044	24.1	45
340	Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer's and Parkinson's disease. *Alzheimer's Research and Therapy*, **2019**, 11, 82	9	26
339	Structural imaging findings on non-enhanced computed tomography are severely underreported in the primary care diagnostic work-up of subjective cognitive decline. *Neuroradiology*, **2019**, 61, 397-404	3.2	4
338	Predicting diagnosis and cognition with F-AV-1451 tau PET and structural MRI in Alzheimer's disease. *Alzheimer's and Dementia*, **2019**, 15, 570-580	1.2	43
337	Elecsys Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. *Clinical Biochemistry*, **2019**, 72, 30-38	3.5	37
336	Method comparison study of the Elecsys Amyloid (1-42) CSF assay versus comparator assays and LC-MS/MS. *Clinical Biochemistry*, **2019**, 72, 7-14	3.5	18
335	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. *JAMA Neurology*, **2019**, 76, 1035-1048	17.2	237
334	Levels of islet amyloid polypeptide in cerebrospinal fluid and plasma from patients with Alzheimer's disease. *PLoS ONE*, **2019**, 14, e0218561	3.7	9
333	A new perspective for advanced positron emission tomography-based molecular imaging in neurodegenerative proteinopathies. *Alzheimer's and Dementia*, **2019**, 15, 1081-1103	1.2	10
332	Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related Amyloid Status. *JAMA Neurology*, **2019**, 76, 1060-1069	17.2	159
331	CSF placental growth factor - a novel candidate biomarker of frontotemporal dementia. *Annals of Clinical and Translational Neurology*, **2019**, 6, 863-872	5.3	4
330	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 997-1004	5.5	13
329	Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2019**, 69, 1213-1220	4.3	8
328	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. *Npj Parkinson's Disease*, **2019**, 5, 7	9.7	24
327	Application of advanced brain positron emission tomography-based molecular imaging for a biological framework in neurodegenerative proteinopathies. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 327-332	5.2	6
326	Advantages and disadvantages of the use of the CSF Amyloid (A)42/40 ratio in the diagnosis of Alzheimer's Disease. *Alzheimer's Research and Therapy*, **2019**, 11, 34	9	145
325	F-Flortaucipir in TDP-43 associated frontotemporal dementia. *Scientific Reports*, **2019**, 9, 6082	4.9	18
324	Mapping of apparent susceptibility yields promising diagnostic separation of progressive supranuclear palsy from other causes of parkinsonism. *Scientific Reports*, **2019**, 9, 6079	4.9	8

323	Extreme sleep pattern in Lewy body dementia: a hypothalamic matter?. *BMJ Case Reports*, **2019**, 12,	0.9	2
322	Association Between Earliest Amyloid Uptake and Functional Connectivity in Cognitively Unimpaired Elderly. *Cerebral Cortex*, **2019**, 29, 2173-2182	5.1	19
321	Searching for the neurite density with diffusion MRI: Challenges for biophysical modeling. *Human Brain Mapping*, **2019**, 40, 2529-2545	5.9	69
320	CSF and blood biomarkers for Parkinson's disease. *Lancet Neurology, The*, **2019**, 18, 573-586	24.1	180
319	Association of IL1RAP-related genetic variation with cerebrospinal fluid concentration of Alzheimer-associated tau protein. *Scientific Reports*, **2019**, 9, 2460	4.9	2
318	Regional times to equilibria and their impact on semi-quantification of [F]AV-1451 uptake. *Journal of Cerebral Blood Flow and Metabolism*, **2019**, 39, 2223-2232	7.3	5
317	Amyloid pathology and hippocampal atrophy are independently associated with memory function in cognitively healthy elderly. *Scientific Reports*, **2019**, 9, 11180	4.9	15
316	European Ultrahigh-Field Imaging Network for Neurodegenerative Diseases (EUFIND). *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2019**, 11, 538-549	5.2	9
315	Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. *Parkinsonism and Related Disorders*, **2019**, 66, 158-165	3.6	5
314	Determining clinically meaningful decline in preclinical Alzheimer disease. *Neurology*, **2019**, 93, e322-e333	9.5	40
313	Use of the tau protein-to-peptide ratio in CSF to improve diagnostic classification of Alzheimer's disease.. *Clinical Mass Spectrometry*, **2019**, 14 Pt B, 74-82	1.9	1
312	Staging Amyloid Pathology With Amyloid Positron Emission Tomography. *JAMA Neurology*, **2019**, 76, 1319-1329	17.2	71
311	Towards a unified protocol for handling of CSF before Amyloid measurements. *Alzheimer's Research and Therapy*, **2019**, 11, 63	9	26
310	Engineered antibodies: new possibilities for brain PET?. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 2848-2858	8.8	27
309	Synuclein-lipoprotein interactions and elevated ApoE level in cerebrospinal fluid from Parkinson's disease patients. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 15226-15235	11.5	14
308	Diffusion Tensor MRI to Distinguish Progressive Supranuclear Palsy from Synucleinopathies. *Radiology*, **2019**, 293, 646-653	20.5	10
307	Autocatalytic amplification of Alzheimer-associated A42 peptide aggregation in human cerebrospinal fluid. *Communications Biology*, **2019**, 2, 365	6.7	28
306	Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. *EMBO Molecular Medicine*, **2019**, 11, e11170	12	113

305	Multiplex proteomics identifies novel CSF and plasma biomarkers of early Alzheimer's disease. *Acta Neuropathologica Communications*, **2019**, 7, 169	7.3	58
304	A quick test of cognitive speed can predict development of dementia in Parkinson's disease. *Scientific Reports*, **2019**, 9, 15417	4.9	5
303	Midlife physical activity is associated with lower incidence of vascular dementia but not Alzheimer's disease. *Alzheimer's Research and Therapy*, **2019**, 11, 87	9	11
302	Amyloid and tau accumulate across distinct spatial networks and are differentially associated with brain connectivity. *ELife*, **2019**, 8,	8.9	27
301	A Deep Learning Approach to MR-less Spatial Normalization for Tau PET Images. *Lecture Notes in Computer Science*, **2019**, 355-363	0.9	1
300	P4-531: CEREBROSPINAL FLUID APOLIPOPROTEIN E ISOFORM CONCENTRATIONS IN RELATION TO ᵦAMYLOID POSITIVITY **2019**, 15, P1517-P1519		
299	P4-540: CSF PTAU-217 PERFORMS BETTER THAN PTAU-181 IN DETECTING ABNORMAL RETENTION OF 18F-FLORTAUCIPIR AND DISCRIMINATING ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS **2019**, 15, P1523-P1523		0
298	DT-01-04: DIAGNOSTIC PERFORMANCE OF [18F]RO948 PET IN THE SEPARATION OF ALZHEIMER'S DISEASE FROM OTHER NEURODEGENERATIVE DISORDERS: FINDINGS FROM THE BIOFINDER-2 STUDY **2019**, 15, P1485-P1486		
297	Cognitively normal women with Alzheimer's disease proteinopathy show relative preservation of memory but not of hippocampal volume. *Alzheimer's Research and Therapy*, **2019**, 11, 109	9	9
296	Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aᵦ(1-42), pTau and tTau CSF immunoassays. *Scientific Reports*, **2019**, 9, 19024	4.9	50
295	Brain myoinositol as a potential marker of amyloid-related pathology: A longitudinal study. *Neurology*, **2019**, 92, e395-e405	6.5	16
294	Associations between tau, Aᵦ and cortical thickness with cognition in Alzheimer disease. *Neurology*, **2019**, 92, e601-e612	6.5	125
293	Data-driven approaches for tau-PET imaging biomarkers in Alzheimer's disease. *Human Brain Mapping*, **2019**, 40, 638-651	5.9	17
292	Accurate risk estimation of ᵦamyloid positivity to identify prodromal Alzheimer's disease: Cross-validation study of practical algorithms. *Alzheimer's and Dementia*, **2019**, 15, 194-204	1.2	31
291	Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer's disease. *Acta Neuropathologica*, **2019**, 137, 279-296	14.3	79
290	Correlation of In Vivo [18F]Flortaucipir With Postmortem Alzheimer Disease Tau Pathology. *JAMA Neurology*, **2019**, 76, 310-317	17.2	50
289	Parkinson's disease: evolution of cognitive impairment and CSF Aᵦ profiles in a prospective longitudinal study. *Journal of Neurology, Neurosurgery and Psychiatry*, **2019**, 90, 165-170	5.5	7
288	Exploring causality of the association between smoking and Parkinson's disease. *International Journal of Epidemiology*, **2019**, 48, 912-925	7.8	38

287	CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts. *Alzheimer's and Dementia*, **2018**, 14, 1470-1481	1.2	266
286	Amyloid blood biomarker detects Alzheimer's disease. *EMBO Molecular Medicine*, **2018**, 10,	12	100
285	Alteration of putaminal fractional anisotropy in Parkinson's disease: a longitudinal diffusion kurtosis imaging study. *Neuroradiology*, **2018**, 60, 247-254	3.2	18
284	Amyloid pathology in the progression to mild cognitive impairment. *Neurobiology of Aging*, **2018**, 64, 76-84	5.6	17
283	Comparing F-AV-1451 with CSF t-tau and p-tau for diagnosis of Alzheimer disease. *Neurology*, **2018**, 90, e388-e395	6.5	62
282	Altered structural network organization in cognitively normal individuals with amyloid pathology. *Neurobiology of Aging*, **2018**, 64, 15-24	5.6	20
281	Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review. *Alzheimer's Research and Therapy*, **2018**, 10, 2	9	20
280	Is longitudinal tau PET ready for use in Alzheimer's disease clinical trials?. *Brain*, **2018**, 141, 1241-1244	11.2	6
279	Amyloid Network Topology Characterizes the Progression of Alzheimer's Disease During the Predementia Stages. *Cerebral Cortex*, **2018**, 28, 340-349	5.1	18
278	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. *Alzheimer's and Dementia*, **2018**, 14, 913-924	1.2	36
277	F-AV-1451 in Parkinson's Disease with and without dementia and in Dementia with Lewy Bodies. *Scientific Reports*, **2018**, 8, 4717	4.9	40
276	Striatal changes in Parkinson disease: An investigation of morphology, functional connectivity and their relationship to clinical symptoms. *Psychiatry Research - Neuroimaging*, **2018**, 275, 5-13	2.9	22
275	Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people. *Alzheimer's and Dementia*, **2018**, 14, 54-61	1.2	13
274	Abnormal Structural Brain Connectome in Individuals with Preclinical Alzheimer's Disease. *Cerebral Cortex*, **2018**, 28, 3638-3649	5.1	21
273	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. *Alzheimer's and Dementia*, **2018**, 14, 1313-1333	1.2	61
272	CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. *Neurology*, **2018**, 91, e867-e877	6.5	120
271	Effects of APOE ε4 on neuroimaging, cerebrospinal fluid biomarkers, and cognition in prodromal Alzheimer's disease. *Neurobiology of Aging*, **2018**, 71, 81-90	5.6	8
270	Molecular properties underlying regional vulnerability to Alzheimer's disease pathology. *Brain*, **2018**, 141, 2755-2771	11.2	65

269	Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease. *Alzheimer's Research and Therapy*, **2018**, 10, 9	9	10
268	Greater tau load and reduced cortical thickness in APOE ε4-negative Alzheimer's disease: a cohort study. *Alzheimer's Research and Therapy*, **2018**, 10, 77	9	36
267	The clinical significance of 10-m walk test standardizations in Parkinson's disease. *Journal of Neurology*, **2018**, 265, 1829-1835	5.5	18
266	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. *JAMA Psychiatry*, **2018**, 75, 84-95	14.5	94
265	Increased midlife triglycerides predict brain β-amyloid and tau pathology 20 years later. *Neurology*, **2018**, 90, e73-e81	6.5	44
264	P3-413: HETEROGENEOUS TAU-PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY **2018**, 14, P1263-P1264		
263	P3-267: ANALYSIS OF CEREBROSPINAL FLUID (CSF) BIOMARKERS TO PREDICT RISK OF CLINICAL DECLINE AND PROGRESSION TO DEMENTIA IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND MILD COGNITIVE SYMPTOMS **2018**, 14, P1178-P1179		1
262	IC-P-224: HETEROGENEOUS TAU-PET SIGNAL IN THE HIPPOCAMPUS HELPS RESOLVE DISCREPANCIES BETWEEN IMAGING AND PATHOLOGY **2018**, 14, P182-P183		
261	O2-09-02: A UNIFIED PRE-ANALYTICAL PROTOCOL FOR HANDLING OF CSF SAMPLES BEFORE ANALYSES OF AD BIOMARKER LEVELS **2018**, 14, P641-P641		
260	IC-P-036: POSITIVE ASSOCIATION BETWEEN THE EARLIEST STAGE OF AMYLOID UPTAKE AND FUNCTIONAL CONNECTIVITY IN NON-DEMENTED ELDERLY SUBJECTS **2018**, 14, P39-P39		
259	Genetic characterization of amyloid-β and tau network spread. *Nature Medicine*, **2018**, 24, 1790-1792	50.5	1
258	Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. *Annals of Neurology*, **2018**, 84, 729-740	9.4	74
257	Dietary intervention with an Okinawan-based Nordic diet in type 2 diabetes renders decreased interleukin-18 concentrations and increased neurofilament light concentrations in plasma. *Nutrition Research*, **2018**, 60, 13-25	4	7
256	Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders. *Scientific Reports*, **2018**, 8, 13276	4.9	59
255	Discriminative Accuracy of [18F]flortaucipir Positron Emission Tomography for Alzheimer Disease vs Other Neurodegenerative Disorders. *JAMA - Journal of the American Medical Association*, **2018**, 320, 1151-1162	27.4	173
254	Endogenous beta-cell CART regulates insulin secretion and transcription of beta-cell genes. *Molecular and Cellular Endocrinology*, **2017**, 447, 52-60	4.4	8
253	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. *Hippocampus*, **2017**, 27, 653-667	3.5	18
252	Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder. *Neurology*, **2017**, 88, 930-937	6.5	240

251	Characterisation of artefacts and drop-in events using STR-validator and single-cell analysis. *Forensic Science International: Genetics*, **2017**, 30, 57-65	4.3	11
250	Biomarkers of microvascular endothelial dysfunction predict incident dementia: a population-based prospective study. *Journal of Internal Medicine*, **2017**, 282, 94-101	10.8	16
249	Increased basal ganglia binding of F-AV-1451 in patients with progressive supranuclear palsy. *Movement Disorders*, **2017**, 32, 108-114	7	93
248	Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer's disease. *Neurobiology of Aging*, **2017**, 58, 14-29	5.6	66
247	Tau oligomers in cerebrospinal fluid in Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2017**, 4, 226-235	5.3	40
246	Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. *Brain*, **2017**, 140, e33	11.2	2
245	Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. *Neurobiology of Aging*, **2017**, 52, 196-213	5.6	73
244	Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. *Acta Neuropathologica*, **2017**, 133, 149-151	14.3	50
243	Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer's disease. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E200-E208	11.5	134
242	Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype. *Neurobiology of Aging*, **2017**, 51, 104-112	5.6	115
241	Characterization of degradation and heterozygote balance by simulation of the forensic DNA analysis process. *International Journal of Legal Medicine*, **2017**, 131, 303-317	3.1	15
240	Mass Spectrometric Analysis of Cerebrospinal Fluid Ubiquitin in Alzheimer's Disease and Parkinsonian Disorders. *Proteomics - Clinical Applications*, **2017**, 11, 1700100	3.1	19
239	Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. *Nature Communications*, **2017**, 8, 1214	17.4	348
238	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. *Scientific Reports*, **2017**, 7, 13333	4.9	33
237	[IC-02-05]: ABNORMAL STRUCTURAL BRAIN CONNECTOME IN INDIVIDUALS WITH PRECLINICAL ALZHEIMER's DISEASE **2017**, 13, P7-P7		2
236	The effect of white matter hyperintensities on statistical analysis of diffusion tensor imaging in cognitively healthy elderly and prodromal Alzheimer's disease. *PLoS ONE*, **2017**, 12, e0185239	3.7	22
235	Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations. *Alzheimer's Research and Therapy*, **2017**, 9, 87	9	16
234	N-Terminal Prosomatostatin and Risk of Vascular Dementia. *Cerebrovascular Diseases*, **2017**, 44, 259-265	3.2	5

233	CSF/serum albumin ratio in dementias: a cross-sectional study on 1861 patients. *Neurobiology of Aging*, **2017**, 59, 1-9	5.6	52
232	No independent association between pulse wave velocity and dementia: a population-based, prospective study. *Journal of Hypertension*, **2017**, 35, 2462-2467	1.9	11
231	In vivo retention of F-AV-1451 in corticobasal syndrome. *Neurology*, **2017**, 89, 845-853	6.5	79
230	F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. *EMBO Molecular Medicine*, **2017**, 9, 1212-1223	12	124
229	Cerebrospinal fluid biomarkers for the diagnosis and prognosis of Parkinson's disease: protocol for a systematic review and individual participant data meta-analysis. *BMJ Open*, **2017**, 7, e018177	3	3
228	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. *Lancet Neurology, The*, **2017**, 16, 661-676	24.1	308
227	MRI of the Swallow Tail Sign: A Useful Marker in the Diagnosis of Lewy Body Dementia?. *American Journal of Neuroradiology*, **2017**, 38, 1737-1741	4.4	33
226	Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, βsynuclein, and total tau in combination with Aβ1-42)/Aβ1-40). *Alzheimer's Research and Therapy*, **2017**, 9, 40	9	12
225	Psychometric testing of a Swedish version of the Apathy Evaluation Scale. *Nordic Journal of Psychiatry*, **2017**, 71, 477-484	2.3	4
224	Heterozygous PINK1 p.G411S increases risk of Parkinson's disease via a dominant-negative mechanism. *Brain*, **2017**, 140, 98-117	11.2	88
223	Modeling Strategies for Quantification of In Vivo F-AV-1451 Binding in Patients with Tau Pathology. *Journal of Nuclear Medicine*, **2017**, 58, 623-631	8.9	46
222	Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. *JAMA Neurology*, **2017**, 74, 1492-1501	17.2	67
221	[IC-P-123]: ATROPHY OF THE POSTERIOR SUBICULUM IS ASSOCIATED WITH MEMORY IMPAIRMENT, TAU AND Aβ PATHOLOGY IN NON-DEMENTED INDIVIDUALS **2017**, 13, P94-P94		
220	[P3‐132]: CSF BIOMARKERS OF NEUROINFLAMMATION ARE ELEVATED IN PRECLINICAL AND PRODROMAL AD AND CORRELATE WITH TAU PATHOLOGY **2017**, 13, P985-P985		
219	[P3‐402]: PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE AND AMYLOID PATHOLOGY EXHIBIT SIGNIFICANT BRAIN ATROPHY, TAU PATHOLOGY AND MILD MEMORY DIFFICULTIES **2017**, 13, P1117-P1117		
218	[P4‐152]: DIFFERENCES IN ANALYTICAL SELECTIVITY OF βAMYLOID (1‐42) IMMUNOASSAYS EXPLAIN DISCORDANT RESULTS IN STUDY COMPARISONS **2017**, 13, P1316-P1317		1
217	[P4‐197]: EMERGING AMYLOID PATHOLOGY **2017**, 13, P1340-P1340		
216	[P1‐150]: INVESTIGATION OF THE ASSOCIATION BETWEEN GENETIC VARIATION IN IL1RAP AND ALZHEIMER's-RELATED CSF-BIOMARKERS **2017**, 13, P300-P300		

215	[IC-P-098]: ASSOCIATION BETWEEN CEREBROSPINAL FLUID AND PLASMA NEURODEGENERATION BIOMARKERS WITH BRAIN ATROPHY IN ALZHEIMER's DISEASE **2017**, 13, P75-P75		
214	[IC-P-199]: ^{18}F-AV-1451 PET IN CLINICALLY DIAGNOSED CORTICOBASAL DEGENERATION **2017**, 13, P146-P147		
213	[P2046]: NOVEL CSF FRAGMENTS OF TAU: CANDIDATE BIOMARKERS OF ALZHEIMER's DISEASE AND TAUOPATHIES **2017**, 13, P706-P707		
212	Distinct 18F-AV-1451 tau PET retention patterns in early- and late-onset Alzheimer's disease. *Brain*, **2017**, 140, 2286-2294	11.2	94
211	Atrophy of the Posterior Subiculum Is Associated with Memory Impairment, Tau- and Aβ Pathology in Non-demented Individuals. *Frontiers in Aging Neuroscience*, **2017**, 9, 306	5.3	22
210	Tau Pathology Distribution in Alzheimer's disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks. *Frontiers in Neuroscience*, **2017**, 11, 167	5.1	47
209	Time to Amyloid Positivity and Preclinical Changes in Brain Metabolism, Atrophy, and Cognition: Evidence for Emerging Amyloid Pathology in Alzheimer's Disease. *Frontiers in Neuroscience*, **2017**, 11, 281	5.1	47
208	Preclinical Amyloid-β and Axonal Degeneration Pathology in Delirium. *Journal of Alzheimer's Disease*, **2017**, 55, 371-379	4.3	22
207	Assessing risk for preclinical β amyloid pathology with , cognitive, and demographic information. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2016**, 4, 76-84	5.2	36
206	Reference measurement procedure for CSF amyloid beta (Aβ) and the CSF Aβ/Aβ ratio - a cross-validation study against amyloid PET. *Journal of Neurochemistry*, **2016**, 139, 651-658	6	56
205	The Swedish SCOPA-SLEEP for assessment of sleep disorders in Parkinson's disease and healthy controls. *Quality of Life Research*, **2016**, 25, 2571-2577	3.7	8
204	Plasma β amyloid in Alzheimer's disease and vascular disease. *Scientific Reports*, **2016**, 6, 26801	4.9	290
203	Brain activity and Alzheimer's disease: a complex relationship. *Brain*, **2016**, 139, 2109-10	11.2	2
202	Increased amyloidogenic APP processing in APOE e4-negative individuals with cerebral β amyloidosis. *Nature Communications*, **2016**, 7, 10918	17.4	39
201	Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. *Alzheimer's Research and Therapy*, **2016**, 8, 17	9	75
200	Cerebrospinal fluid Aβ42/Aβ40 and Aβ42/Aβ38 as biomarkers of Alzheimer's disease. *Neurobiology of Aging*, **2016**, 39, S28	5.6	3
199	CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease. *Annals of Clinical and Translational Neurology*, **2016**, 3, 154-65	5.3	244
198	Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson's Disease. *PLoS ONE*, **2016**, 11, e0157755	3.7	29

197 — A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2016**, 53, 1353-63 — 4.3 — 19

196 — Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes. *Journal of Alzheimer's Disease*, **2016**, 53, 1121-32 — 4.3 — 43

195 — 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. *Brain*, **2016**, 139, 2372-9 — 11.2 — 120

194 — Reply: Do we still need positron emission tomography for early Alzheimer's disease diagnosis?. *Brain*, **2016**, 139, e61 — 11.2 — 4

193 — Cerebral white matter lesions - associations with Aβ isoforms and amyloid PET. *Scientific Reports*, **2016**, 6, 20709 — 4.9 — 41

192 — Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease. *EMBO Molecular Medicine*, **2016**, 8, 1184-1196 — 12 — 152

191 — Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer's Disease Patient with Presenilin-1 Mutation. *Journal of Alzheimer's Disease*, **2016**, 51, 339-43 — 4.3 — 28

190 — P4-339: Early- and Late-Onset Alzheimer's Disease are Associated with Distinct Regional TAU Pathology as Examined with ^{18}F-AV-1451 TAU Positron Emission Tomography **2016**, 12, P1164-P1165

189 — Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism. *Journal of Parkinson's Disease*, **2016**, 6, 99-108 — 5.3 — 4

188 — The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer's disease. *Alzheimer's Research and Therapy*, **2016**, 8, 41 — 9 — 78

187 — Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. *Brain*, **2016**, 139, 1226-36 — 11.2 — 229

186 — Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease. *Neurology*, **2016**, 86, 1754-61 — 6.5 — 48

185 — Clinical validity of CSF biomarkers for Alzheimer's disease: necessary indeed, but sufficient?. *Lancet Neurology, The*, **2016**, 15, 650-651 — 24.1 — 8

184 — Increased CSF biomarkers of angiogenesis in Parkinson disease. *Neurology*, **2016**, 86, 1747-8 — 6.5 — 3

183 — Cognitive and functional changes associated with Aβ pathology and the progression to mild cognitive impairment. *Neurobiology of Aging*, **2016**, 48, 172-181 — 5.6 — 22

182 — External validation of a 3-step falls prediction model in mild Parkinson's disease. *Journal of Neurology*, **2016**, 263, 2462-2469 — 5.5 — 20

181 — Plasma tau in Alzheimer disease. *Neurology*, **2016**, 87, 1827-1835 — 6.5 — 269

180 — Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer's disease. *Annals of Clinical and Translational Neurology*, **2016**, 3, 12-20 — 5.3 — 115

179	Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson's Disease. *Movement Disorders*, **2016**, 31, 898-905	7	94
178	Low IL-8 is associated with anxiety in suicidal patients: genetic variation and decreased protein levels. *Acta Psychiatrica Scandinavica*, **2015**, 131, 269-78	6.5	41
177	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. *Alzheimer's and Dementia*, **2015**, 11, 1180-90	1.2	201
176	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. *Brain*, **2015**, 138, 2701-15	15.2	86
175	Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer's disease. *BMC Neurology*, **2015**, 15, 8	3.1	1
174	Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study. *Alzheimer's and Dementia*, **2015**, 11, 249-57.e1	1.2	66
173	Genotyping and interpretation of STR-DNA: Low-template, mixtures and database matches-Twenty years of research and development. *Forensic Science International: Genetics*, **2015**, 18, 100-17	4.3	90
172	Amyloid biomarkers in Alzheimer's disease. *Trends in Pharmacological Sciences*, **2015**, 36, 297-309	13.2	320
171	Less pronounced response to exercise in healthy relatives to type 2 diabetic subjects compared with controls. *Journal of Applied Physiology*, **2015**, 119, 953-60	3.7	9
170	Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. *Neuroradiology*, **2015**, 57, 1079-91	3.2	32
169	Increased CSF biomarkers of angiogenesis in Parkinson disease. *Neurology*, **2015**, 85, 1834-42	6.5	75
168	Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls. *Alzheimer's Research and Therapy*, **2015**, 7, 40	9	90
167	Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease. *Neurology*, **2015**, 85, 1240-9	6.5	192
166	β-Amyloid peptides and amyloid plaques in Alzheimer's disease. *Neurotherapeutics*, **2015**, 12, 3-11	6.4	121
165	Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer's disease and other neurodegenerative diseases. *EuPA Open Proteomics*, **2015**, 8, 137-143	0.1	23
164	Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study. *Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2015**, 1, 403-11	5.2	16
163	Hepatocyte growth factor in cerebrospinal fluid differentiates community-acquired or nosocomial septic meningitis from other causes of pleocytosis. *Fluids and Barriers of the CNS*, **2015**, 12, 22	7	5
162	Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patients. *Alzheimer's Research and Therapy*, **2015**, 7, 63	9	13

#		IF	Cit
161	Prediction of falls and/or near falls in people with mild Parkinson's disease. *PLoS ONE*, **2015**, 10, e0117018	3.7	45
160	Spatial navigation measured by the Floor Maze Test in patients with subjective cognitive impairment, mild cognitive impairment, and mild Alzheimer's disease. *International Psychogeriatrics*, **2015**, 27, 1401-9	3.4	15
159	Parkinson's Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study. *Neurodegenerative Diseases*, **2015**, 15, 331-8	2.3	8
158	Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-Sectional Cohort Study Evaluating the Effect of Arterial Stiffness. *Cerebrovascular Diseases Extra*, **2015**, 5, 41-51	2.1	25
157	CSF biomarkers and clinical progression of Parkinson disease. *Neurology*, **2015**, 84, 57-63	6.5	126
156	An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease. *Journal of Proteome Research*, **2015**, 14, 654-63	5.6	65
155	The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies. *PLoS ONE*, **2015**, 10, e0135458	3.7	66
154	Extrapolation-Based References Improve Motion and Eddy-Current Correction of High B-Value DWI Data: Application in Parkinson's Disease Dementia. *PLoS ONE*, **2015**, 10, e0141825	3.7	58
153	A porous silicon immunoassay platform for fluorometric determination of α-synuclein in human cerebrospinal fluid. *Mikrochimica Acta*, **2014**, 181, 1143-1149	5.8	7
152	Factors associated with fear of falling in people with Parkinson's disease. *BMC Neurology*, **2014**, 14, 19	3.1	56
151	Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. *Journal of Alzheimer's Disease*, **2014**, 40, 343-50	4.3	11
150	Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. *Acta Neuropathologica*, **2014**, 127, 633-43	14.3	86
149	Extensive changes in the transcriptional profile of human adipose tissue including genes involved in oxidative phosphorylation after a 6-month exercise intervention. *Acta Physiologica*, **2014**, 211, 188-200	5.6	41
148	Assessment of peptide chemical modifications on the development of an accurate and precise multiplex selected reaction monitoring assay for apolipoprotein e isoforms. *Journal of Proteome Research*, **2014**, 13, 1077-87	5.6	41
147	Global genomic and transcriptomic analysis of human pancreatic islets reveals novel genes influencing glucose metabolism. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 13924-9	11.5	297
146	Flt3 ligand does not differentiate between Parkinsonian disorders. *Movement Disorders*, **2014**, 29, 1319-22	7.7	9
145	STR-validator: an open source platform for validation and process control. *Forensic Science International: Genetics*, **2014**, 13, 154-66	4.3	13
144	Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer's disease: an observational study. *BMC Neurology*, **2014**, 14, 64	3.1	34

143	The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. *Alzheimer's and Dementia*, **2014**, 10, 713-723.e2	1.2	204
142	Expression of phosphofructokinase in skeletal muscle is influenced by genetic variation and associated with insulin sensitivity. *Diabetes*, **2014**, 63, 1154-65	0.9	25
141	Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease. *Alzheimer's Research and Therapy*, **2014**, 6, 25	9	130
140	CSF biomarkers for Alzheimer's pathology and the effect size of APOE e4. *Molecular Psychiatry*, **2014**, 19, 148-9	15.1	26
139	P4-023: INCREASED LEVELS OF ANGIOGENIC FACTORS IN THE CEREBROSPINAL FLUID ARE ASSOCIATED WITH COGNITIVE IMPAIRMENT IN PARKINSON'S DISEASE **2014**, 10, P791-P791		
138	P2-101: EVALUATION OF THE PRESYNAPTIC PROTEIN SNAP-25 AS A NOVEL CEREBROSPINAL FLUID MARKER FOR SYNAPTIC PATHOLOGY IN ALZHEIMER'S DISEASE **2014**, 10, P508-P508		
137	Increased levels of hyaluronic acid in cerebrospinal fluid in patients with vascular dementia. *Journal of Alzheimer's Disease*, **2014**, 42, 1435-41	4.3	25
136	SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. *Molecular Neurodegeneration*, **2014**, 9, 53	19	150
135	Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography. *JAMA Neurology*, **2014**, 71, 1282-9	17.2	254
134	Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. *JAMA Psychiatry*, **2014**, 71, 1183-91	14.5	65
133	Fluid biomarkers in Alzheimer's disease - current concepts. *Molecular Neurodegeneration*, **2013**, 8, 20	19	147
132	Plasma tau levels in Alzheimer's disease. *Alzheimer's Research and Therapy*, **2013**, 5, 9	9	262
131	NG2 cells, a new trail for Alzheimer's disease mechanisms?. *Acta Neuropathologica Communications*, **2013**, 1, 7	7.3	37
130	Evaluation of the cerebrospinal fluid amyloid-β-42/amyloid-β-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders. *Dementia and Geriatric Cognitive Disorders*, **2013**, 36, 99-110	2.6	37
129	Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease. *Brain Research*, **2013**, 1513, 117-26	3.7	38
128	Free open source software for internal validation of forensic STR typing kits. *Forensic Science International: Genetics Supplement Series*, **2013**, 4, e300-e301	0.5	1
127	Aβ-15/16 as a potential diagnostic marker in neurodegenerative diseases. *NeuroMolecular Medicine*, **2013**, 15, 169-79	4.6	10
126	Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease. *Psychoneuroendocrinology*, **2013**, 38, 1729-37	5	51

125	Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease. *Psychoneuroendocrinology*, **2013**, 38, 1058-66	5	30
124	Cerebrospinal fluid inflammatory markers in Parkinson's disease--associations with depression, fatigue, and cognitive impairment. *Brain, Behavior, and Immunity*, **2013**, 33, 183-9	16.6	166
123	Altered chemokine levels in the cerebrospinal fluid and plasma of suicide attempters. *Psychoneuroendocrinology*, **2013**, 38, 853-62	5	37
122	Link between GIP and osteopontin in adipose tissue and insulin resistance. *Diabetes*, **2013**, 62, 2088-94	0.9	64
121	A selected reaction monitoring (SRM)-based method for absolute quantification of Aβ8, Aβ0, and Aβ2 in cerebrospinal fluid of Alzheimer's disease patients and healthy controls. *Journal of Alzheimer's Disease*, **2013**, 33, 1021-32	4.3	86
120	Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies. *International Journal of Geriatric Psychiatry*, **2013**, 28, 738-44	3.9	19
119	Tau pathology and parietal white matter lesions have independent but synergistic effects on early development of Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders Extra*, **2013**, 3, 113-22	2.5	18
118	Prediagnostic body fat and risk of death from amyotrophic lateral sclerosis: the EPIC cohort. *Neurology*, **2013**, 80, 829-38	6.5	103
117	Diagnostic power of 24S-hydroxycholesterol in cerebrospinal fluid: candidate marker of brain health. *Journal of Alzheimer's Disease*, **2013**, 36, 739-47	4.3	28
116	Cerebrospinal fluid levels of heart fatty acid binding protein are elevated prodromally in Alzheimer's disease and vascular dementia. *Journal of Alzheimer's Disease*, **2013**, 34, 673-9	4.3	32
115	Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. *PLoS ONE*, **2013**, 8, e53250	3.7	102
114	Proinflammatory cytokines are elevated in serum of patients with multiple system atrophy. *PLoS ONE*, **2013**, 8, e62354	3.7	28
113	Assessment of global and regional diffusion changes along white matter tracts in parkinsonian disorders by MR tractography. *PLoS ONE*, **2013**, 8, e66022	3.7	24
112	Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease. *PLoS ONE*, **2013**, 8, e81989	3.7	36
111	Microglial markers are elevated in the prodromal phase of Alzheimer's disease and vascular dementia. *Journal of Alzheimer's Disease*, **2013**, 33, 45-53	4.3	91
110	Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease. *PLoS ONE*, **2013**, 8, e66381	3.7	93
109	Age and diagnostic performance of Alzheimer disease CSF biomarkers. *Neurology*, **2012**, 78, 468-76	6.5	133
108	Evaluation of plasma Aβ as predictor of Alzheimer's disease in older individuals without dementia: a population-based study. *Journal of Alzheimer's Disease*, **2012**, 28, 231-8	4.3	37

107	Telomere length in blood and skeletal muscle in relation to measures of glycaemia and insulinaemia. *Diabetic Medicine*, **2012**, 29, e377-81	3.5	18
106	Body mass index is associated with biological CSF markers of core brain pathology of Alzheimer's disease. *Neurobiology of Aging*, **2012**, 33, 1599-608	5.6	38
105	Impact of an exercise intervention on DNA methylation in skeletal muscle from first-degree relatives of patients with type 2 diabetes. *Diabetes*, **2012**, 61, 3322-32	0.9	274
104	First-degree relatives of type 2 diabetic patients have reduced expression of genes involved in fatty acid metabolism in skeletal muscle. *Journal of Clinical Endocrinology and Metabolism*, **2012**, 97, E1332-7	5.6	16
103	CSF biomarkers correlate with cerebral blood flow on SPECT in healthy elderly. *Dementia and Geriatric Cognitive Disorders*, **2012**, 33, 156-63	2.6	10
102	Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. *Archives of Neurology*, **2012**, 69, 1445-52		327
101	Identification of SPARC-like 1 protein as part of a biomarker panel for Alzheimer's disease in cerebrospinal fluid. *Journal of Alzheimer's Disease*, **2012**, 28, 625-36	4.3	49
100	Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease. *Journal of Alzheimer's Disease*, **2012**, 29, 171-6	4.3	78
99	Comparison of brief cognitive tests and CSF biomarkers in predicting Alzheimer's disease in mild cognitive impairment: six-year follow-up study. *PLoS ONE*, **2012**, 7, e38639	3.7	56
98	Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease. *PLoS ONE*, **2012**, 7, e29868	3.7	79
97	Non-motor symptoms in patients with Parkinson's disease - correlations with inflammatory cytokines in serum. *PLoS ONE*, **2012**, 7, e47387	3.7	131
96	Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease. *Journal of Neural Transmission*, **2012**, 119, 789-97	4.3	47
95	Monte Carlo feature selection and rule-based models to predict Alzheimer's disease in mild cognitive impairment. *Journal of Neural Transmission*, **2012**, 119, 821-31	4.3	10
94	Leukocyte telomere length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's disease: a pilot study. *Experimental Gerontology*, **2012**, 47, 179-82	4.5	35
93	Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. *Archives of General Psychiatry*, **2012**, 69, 98-106		459
92	CCL2 is associated with a faster rate of cognitive decline during early stages of Alzheimer's disease. *PLoS ONE*, **2012**, 7, e30525	3.7	158
91	No diagnostic value of plasma clusterin in Alzheimer's disease. *PLoS ONE*, **2012**, 7, e50237	3.7	32
90	Evaluation of GeneMapper ID-X Mixture Analysis tool. *Forensic Science International: Genetics Supplement Series*, **2011**, 3, e11-e12	0.5	4

89	Antihypertensive therapy is associated with reduced rate of conversion to Alzheimer's disease in midregional proatrial natriuretic peptide stratified subjects with mild cognitive impairment. *Biological Psychiatry*, **2011**, 70, 145-51	7.9	18
88	Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. *International Journal of Alzheimer's Disease*, **2011**, 2011, 495025	3.7	16
87	Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. *Frontiers in Aging Neuroscience*, **2011**, 3, 1	5.3	53
86	Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. *Journal of Alzheimer's Disease*, **2011**, 24, 537-46	4.3	62
85	Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women. *Clinical Endocrinology*, **2011**, 75, 301-8	3.4	8
84	Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility. *NeuroMolecular Medicine*, **2011**, 13, 151-9	4.6	89
83	Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. *International Journal of Geriatric Psychiatry*, **2011**, 26, 206-13	3.9	18
82	Differences in survival between patients with dementia with Lewy bodies and patients with Alzheimer's disease--measured from a fixed cognitive level. *Dementia and Geriatric Cognitive Disorders*, **2011**, 32, 408-16	2.6	22
81	Pleiotropic effects of GIP on islet function involve osteopontin. *Diabetes*, **2011**, 60, 2424-33	0.9	72
80	Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide: a retrospective analysis of 134 patients with mild cognitive impairment. *Journal of Clinical Psychiatry*, **2011**, 72, 556-63	4.6	23
79	Higher cathepsin B levels in plasma in Alzheimer's disease compared to healthy controls. *Journal of Alzheimer's Disease*, **2010**, 22, 1223-30	4.3	49
78	Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls. *Journal of Alzheimer's Disease*, **2010**, 21, 471-8	4.3	21
77	Converging pathways of chromogranin and amyloid metabolism in the brain. *Journal of Alzheimer's Disease*, **2010**, 20, 1039-49	4.3	17
76	Correlation of longitudinal cerebrospinal fluid biomarkers with cognitive decline in healthy older adults. *Archives of Neurology*, **2010**, 67, 217-23		72
75	Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. *Archives of Neurology*, **2010**, 67, 949-56		344
74	Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years. *Neurobiology of Aging*, **2010**, 31, 215-23	5.6	65
73	Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. *Neurobiology of Aging*, **2010**, 31, 357-67	5.6	197
72	Soluble TNF receptors are associated with Aβ metabolism and conversion to dementia in subjects with mild cognitive impairment. *Neurobiology of Aging*, **2010**, 31, 1877-84	5.6	85

71	CSF biomarkers predict a more malignant outcome in Alzheimer disease. *Neurology*, **2010**, 74, 1531-7	6.5	141
70	Low incidence of post-lumbar puncture headache in 1,089 consecutive memory clinic patients. *European Neurology*, **2010**, 63, 326-30	2.1	85
69	A Quick Test of cognitive speed is sensitive in detecting early treatment response in Alzheimer's disease. *Alzheimer's Research and Therapy*, **2010**, 2, 29	9	25
68	Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease. *Alzheimer's Research and Therapy*, **2010**, 2, 20	9	54
67	Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years. *Journal of Alzheimer's Disease*, **2010**, 21, 1119-28	4.3	94
66	Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease. *Brain Research*, **2010**, 1362, 13-22	3.7	156
65	Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity. *International Journal of Geriatric Psychiatry*, **2010**, 25, 403-10	3.9	83
64	Distinct cerebrospinal fluid amyloid beta peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease. *Molecular Neurodegeneration*, **2010**, 5, 2	19	66
63	Aβ40 oligomers identified as a potential biomarker for the diagnosis of Alzheimer's disease. *PLoS ONE*, **2010**, 5, e15725	3.7	82
62	Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies. *Dementia and Geriatric Cognitive Disorders*, **2009**, 28, 314-9	2.6	28
61	Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?. *International Journal of Geriatric Psychiatry*, **2009**, 24, 638-47	3.9	28
60	Practical suggestions on how to differentiate dementia with Lewy bodies from Alzheimer's disease with common cognitive tests. *International Journal of Geriatric Psychiatry*, **2009**, 24, 1405-12	3.9	61
59	Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. *Journal of Nutrition, Health and Aging*, **2009**, 13, 205-8	5.2	37
58	Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. *Neurobiology of Aging*, **2009**, 30, 165-73	5.6	61
57	CSF Mg and Ca as diagnostic markers for dementia with Lewy bodies. *Neurobiology of Aging*, **2009**, 30, 1265-71	5.6	34
56	Elevated plasma levels of soluble CD40 in incipient Alzheimer's disease. *Neuroscience Letters*, **2009**, 450, 56-9	3.3	30
55	Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. *Biological Psychiatry*, **2009**, 66, 287-92	7.9	361
54	Trace DNA collection-Performance of minitape and three different swabs. *Forensic Science International: Genetics Supplement Series*, **2009**, 2, 189-190	0.5	37

53	CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. *JAMA - Journal of the American Medical Association*, **2009**, 302, 385-93	27.4	758
52	Longitudinal study of CSF biomarkers in patients with Alzheimer's disease. *PLoS ONE*, **2009**, 4, e6294	3.7	60
51	A fast analysis system for forensic DNA reference samples. *Forensic Science International: Genetics*, **2008**, 2, 184-9	4.3	20
50	A comparison of three automated DNA purification methods in Forensic casework. *Forensic Science International: Genetics Supplement Series*, **2008**, 1, 76-77	0.5	10
49	Automatic data processing of reference DNA-profiles from FTA and non-FTA samples. *Forensic Science International: Genetics Supplement Series*, **2008**, 1, 29-31	0.5	1
48	Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease. *Archives of Neurology*, **2008**, 65, 1102-7		162
47	Prediction of Alzheimer's disease using a cerebrospinal fluid pattern of C-terminally truncated beta-amyloid peptides. *Neurodegenerative Diseases*, **2008**, 5, 268-76	2.3	27
46	Predicting long-term cognitive outcome with new regression models in donepezil-treated Alzheimer patients in a naturalistic setting. *Dementia and Geriatric Cognitive Disorders*, **2008**, 26, 203-11	2.6	15
45	Cube copying test in combination with rCBF or CSF A beta 42 predicts development of Alzheimer's disease. *Dementia and Geriatric Cognitive Disorders*, **2008**, 25, 544-52	2.6	15
44	Electroencephalogram variability in dementia with lewy bodies, Alzheimer's disease and controls. *Dementia and Geriatric Cognitive Disorders*, **2008**, 26, 284-90	2.6	46
43	The usefulness of cube copying for evaluating treatment of Alzheimer's disease. *American Journal of Alzheimer's Disease and Other Dementias*, **2008**, 23, 439-46	2.5	8
42	The period of hypotension following orthostatic challenge is prolonged in dementia with Lewy bodies. *International Journal of Geriatric Psychiatry*, **2008**, 23, 192-8	3.9	38
41	Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. *Dementia and Geriatric Cognitive Disorders*, **2007**, 23, 316-20	2.6	204
40	Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. *Archives of Neurology*, **2007**, 64, 366-70		104
39	Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. *Dementia and Geriatric Cognitive Disorders*, **2007**, 24, 118-24	2.6	120
38	Kinesin gene variability may affect tau phosphorylation in early Alzheimer's disease. *International Journal of Molecular Medicine*, **2007**, 20, 233	4.4	2
37	Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. *Lancet Neurology, The*, **2006**, 5, 228-34	24.1	1254
36	Lack of neuroprotection by heat shock protein 70 overexpression in a mouse model of global cerebral ischemia. *Experimental Brain Research*, **2004**, 154, 442-9	2.3	32

35	Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression. *Brain Research*, **2003**, 970, 47-57	3.7	106
34	Cyclosporin A and Bcl-2 do not inhibit quinolinic acid-induced striatal excitotoxicity in rodents. *Experimental Neurology*, **2003**, 183, 430-7	5.7	9
33	Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. *Neuron*, **2002**, 33, 849-60	13.9	506
32	Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length. *Journal of Neurochemistry*, **2001**, 78, 694-703	6	45
31	Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice. *European Journal of Neuroscience*, **2001**, 13, 206-10	3.5	73
30	Mice transgenic for exon 1 of the Huntington's disease gene display reduced striatal sensitivity to neurotoxicity induced by dopamine and 6-hydroxydopamine. *European Journal of Neuroscience*, **2001**, 14, 1425-35	3.5	34
29	Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the huntington gene. *European Journal of Neuroscience*, **2001**, 14, 1492-504	3.5	117
28	Improving the survival of grafted dopaminergic neurons: a review over current approaches. *Cell Transplantation*, **2000**, 9, 179-95	4	287
27	Grafting of nigral tissue hibernated with tirilazad mesylate and glial cell line-derived neurotrophic factor. *Cell Transplantation*, **2000**, 9, 577-84	4	16
26	Expression of TGF-beta isoforms, TGF-beta receptors, and SMAD molecules at different stages of human glioma. *International Journal of Cancer*, **2000**, 89, 251-8	7.5	181
25	Oxidative stress, mitochondrial permeability transition and activation of caspases in calcium ionophore A23187-induced death of cultured striatal neurons. *Brain Research*, **2000**, 857, 20-9	3.7	81
24	Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease. *Progress in Brain Research*, **2000**, 127, 203-31	2.9	31
23	FK506 and cyclosporin A enhance the survival of cultured and grafted rat embryonic dopamine neurons. *Experimental Neurology*, **2000**, 164, 94-101	5.7	35
22	Additive effects of caspase inhibitor and lazaroid on the survival of transplanted rat and human embryonic dopamine neurons. *Experimental Neurology*, **2000**, 164, 102-11	5.7	69
21	Caspase inhibition reduces apoptosis and increases survival of nigral transplants. *Nature Medicine*, **1999**, 5, 97-100	50.5	258
20	Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 8727-32	11.5	200
19	Flunarizine improves the survival of grafted dopaminergic neurons. *Neuroscience*, **1999**, 94, 17-20	3.9	31
18	Patterns of cell death and dopaminergic neuron survival in intrastriatal nigral grafts. *Experimental Neurology*, **1999**, 160, 279-88	5.7	79

17	Neuronal death in nigral grafts in the absence of poly (ADP-ribose) polymerase activation. *NeuroReport*, **1999**, 10, 3347-51	1.7	10
16	Graft survival. *Journal of Neurosurgery*, **1999**, 90, 804-6	3.2	3
15	Mitochondrial control of acute glutamate excitotoxicity in cultured cerebellar granule cells. *Journal of Neuroscience*, **1998**, 18, 10277-86	6.6	179
14	A CASE OF XXXXY SEX CHROMOSOME ANOMALY WITH AUTORADIOGRAPHIC STUDIES. *Cytogenetic and Genome Research*, **1963**, 2, 208-31	1.9	42
13	Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment		1
12	Diagnostic value of plasma neurofilament light: A multicentre validation study		6
11	Data-driven approaches for Tau-PET imaging biomarkers in Alzheimer's disease		1
10	Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease		1
9	Time between milestone events in the Alzheimer's disease amyloid cascade		1
8	Characterizing the spatiotemporal variability of Alzheimer's disease pathology		5
7	Spread of pathological tau proteins through communicating neurons in human Alzheimer's disease		4
6	Kinetic fingerprints differentiate anti-Aβ therapies		5
5	Plasma glial fibrillary acidic protein is an early marker of Aβ pathology in Alzheimer's disease		2
4	Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures		2
3	Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau		3
2	CSF Aβ38 levels are associated with Alzheimer-related decline: implications for γ-secretase modulators		1
1	Plasma biomarkers of Alzheimer's disease predict cognitive decline and could improve clinical trials in the cognitively unimpaired elderly		1